<?xml version="1.0" encoding="UTF-8"?>
<p>Currently, the only approved NtARTi for the treatment of HIV infection is tenofovir disoproxil fumarate (TDF), the prodrug of tenofovir ((R)-9-(2-phosphonylmethoxypropyl)adenine, (R)-PMPA), which is also a member of the acyclic nucleoside phosphonates [
 <xref rid="B43-vetsci-02-00456" ref-type="bibr">43</xref>,
 <xref rid="B45-vetsci-02-00456" ref-type="bibr">45</xref>]. The antiviral spectrum of tenofovir (2R-1-(6-amino-9H-purin-9-yl)-propan-2-yl-oxy-methyl-phosphonic acid, PMPA) is narrower than that of adefovir; it does not encompass herpesviruses, but is confined to hepadna- and retroviruses [
 <xref rid="B44-vetsci-02-00456" ref-type="bibr">44</xref>]. Tenofovir disoproxil fumarate has become one of the most commonly used drugs in HIV therapy since its licensing in 2001 [
 <xref rid="B5-vetsci-02-00456" ref-type="bibr">5</xref>,
 <xref rid="B9-vetsci-02-00456" ref-type="bibr">9</xref>].
</p>
